Cytotoxic mechanisms of FK317, a new class of bioreductive agent with potent antitumor activity

Japanese Journal of Cancer Research

Volumn 89, Issue 6, 1998, Pages 666-672

  Naoe, Yoshinori ^a   Inami, Masamichi ^a   Kawamura, Ikuo ^a   Nishigaki, Fusako ^a   Tsujimoto, Susumu ^a   Matsumoto, Sanae ^a   Manda, Toshitaka ^a   Shimomura, Kyoichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antitumour effect; Bioreductive agent; Deacetyl metabolite; DT diaphorase; FK317

Indexed keywords

1 ACETYL 8 CARBAMOYLOXYMETHYL 3,9 EPOXY 5 FORMYL 1A,2,3,8,9,9A HEXAHYDRO 9 HYDROXY 7 METHOXY 1H AZIRINO[2,3 C][1]BENZAZOCINE ACETATE; 11 ACETYL 8 CARBAMOYLOXYMETHYL 4 FORMYL 6 METHOXY 14 OXA 1,11 DIAZATETRACYCLO[7,4,1,0,0]TETRADECA 2,4,6 TRIEN 9 YL ACETATE; ANTINEOPLASTIC AGENT; CARBOQUONE; CELL PROTEIN; CISPLATIN; CYTOCHROME P450 REDUCTASE; DICOUMAROL; DNA; DOXORUBICIN; FK 70496; FR 157471; FR 160516; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; CROSS RESISTANCE; DEACETYLATION; DNA BINDING; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DNA BINDING;

EID: 0031817240     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb03269.x     Document Type: Article

References (26)

1. Shimomura, K., Manda, T., Mukumoto, S., Masuda, K., Nakamura, T., Mizota, T., Matsumoto, S., Nishigaki, F., Oku, T., Mori, J. and Shibayama, F. Antitumor activity and hematotoxicity of a new, substituted dihydro-benzoxazine, FK973, in mice. Cancer Res., 48, 1166-1172 (1988).
2. Majima, H., Hasegawa, K., Fukuoka, M., Furuse, K., Wakui, A., Furue, H., Masaoka, T., Hattori, T., Taguchi, T., Ogura, T. and Niitani, H. Phase I clinical and pharmacokinetic study of FK973. Proc. Am. Soc. Clin. Oncol., 9, 78 (1990).
3. Pazdur, R., Ho, D. H., Daugherty, K., Bradner, W. T., Krakoff, I. H. and Raber, M. N. Phase I trial of FK973: description of a delayed vascular leak syndrome. Invest. New Drugs, 9, 337-382 (1991).
4. Lin, A. J., Cosby, L. and Sartorelli, A. C. Potential bioreductive alkylating agents. In "Cancer Chemotherapy," ed. A. C. Sartorelli, pp. 71-80 (1976). ACS Monograph Series, Washington, DC.
5. Tomasz, M., Lipman, R., Chowdary, D., Pawlak, J., Verdine, G. L. and Nakanishi, K. Isolation and structure of a covalent cross-link adduct between Mitomycin C and DNA. Science, 235, 1204-1208 (1987).
6. Long, B. H., Willson, J. K. V., Brattain, D. E., Musial, S. and Brattain, M. G. Effects of mitomycin on human colon carcinoma cells. J. Natl. Cancer Inst., 73, 787-792 (1984).
7. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
8. Kohn, K. W., Ewig, R. A. G., Erickson, L. C. and Zwelling, L. A. Measurement of strand breaks and cross links by alkaline elution. In "DNA Repair," ed. E. C. Friedberg and P. C. Hanowalt, pp. 379-401 (1981). Marcel Dekker, Inc., New York.
9. Williams, R. M. and Scott, R. R. DNA cross-linking studies on FR900482: observations on the mode of activation. Tetrahedron Lett., 33, 2929-2932 (1992).
10. Ernster, L. DT-diaphorase. Methods Enzymol., 10, 309-317 (1967).
11. Benson, A. M., Hunkler, M. J. and Talalay, P. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sci. USA, 77, 5216-5220 (1980).
12. Vermillion, V. L. and Coon, M. I. Purified liver microsomal NADPH-cytochrome P450 reductase. J. Biol. Chem., 253, 2694-2704 (1978).
13. Naoe, Y., Inami, M., Matsumoto, S., Nishigaki, F., Tsujimoto, S., Kawamura, I., Miyayasu, K., Manda, T. and Shimomura, K. FK317; a novel substituted dihydrobenzoxazine with potent antitumor activity and without inducing vascular leak syndrome. Cancer Chemother. Pharmacol. (1998). in press.
14. Kohn, H. Studies concerning the mechanism of electrophilic substitution reaction of mitomycin C. J. Am. Chem. Soc., 105, 4105-4106 (1983).
15. Pan, S. S., Andrews, P. A. and Glover, C. J. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem., 259, 959-966 (1984).
16. Bligh, H. F. J., Bartoszek, A., Robson, C. N., Hickson, I. D., Kasper, C. B., Beggs, J. D. and Wolf, C. R. Activation of mitomycin C by NADPH:cytochrome P-450 reductase. Cancer Res., 50, 7789-7792 (1990).
17. Keyes, S. R., Fracasso, P. M., Heimbook, D. C., Rockwell, S., Sligar, S. G. and Sartorelli, A. C. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res., 44, 5638-5643 (1984).
18. Siegel, D., Beall, H., Senekowitsch, C., Kasai, M., Arai, N., Gibson, N. W. and Ross, D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry, 31, 7879-7885 (1992).
19. Marshall, R. S., Paterson, M. and Rauth, A. M. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancerprone family. Carcinogenesis, 12, 1175-1180 (1991).
20. Keyes, S. R., Rockwell, S. and Sartorelli, A. C. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicumarol in vivo and in vitro. Cancer Res., 45, 213-216 (1985).
21. Malkinson, A. M., Siegel, D., Forrest, G. L., Gazdar, A. F., Oie, H. K., Chan, D. C., Bunn, P. A., Mabry, M., Dykes, D. J., Harrison, S. D., Jr. and Ross, D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res., 52, 4752-4757 (1992).
22. Schlager, J. J. and Powis. G. Cytosolic NAD(P)H: (quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int. J. Cancer, 45, 403-409 (1990).
23. Knox, R. J., Boland, M. P., Friedlos, F., Coles, B., Southan, C. and Roberts, J. J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogcnase (quinone) (EC 1.6.99.2). Biochem. Pharmacol., 37, 4671-4677 (1988).
24. Boland, M. P., Knox, R. J. and Roberts, J. J. The differences in kinetics of rat and human DT diaphorase results in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem. Pharmacol., 41, 867-875 (1991).
25. Fukuyama, T. and Goto, S. Synthetic approaches toward FR-900482. I. Stereoselective synthesis of a pentacyclic model compound. Tetrahedron Lett., 47, 6491-6494 (1989).
26. Masuda, K., Nakamura, T., Shimomura, K., Shibata, T., Terano, H. and Kohsaka, M. A new antitumor antibiotic, FR-900482: V: Interstrand DNA-DNA cross-links in L1210 cells. J. Antibiot. (Tokyo), 41, 1497-1501 (1988).